Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

The content of this section has been developed in collaboration between COR2ED GmbH (an Independent Medical Education Company) and the experts serving as Scientific Directors on this programme:

  • Prof Ezra Cohen (medical oncologist at the Moores Cancer Center, San Diego, USA)
  • Prof. Fernando Lopez-Rios (molecular and surgical pathologist at Hospital Universitario 12 de Octubre, Madrid, Spain)
  • Dr. Jaclyn Hechtman (molecular and surgical pathologist at Memorial Sloan Kettering Cancer Center, New York, USA)
  • Prof. Frederique Penault-Llorca (molecular and surgical pathologist at the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France)
  • Assoc. Prof. Gerald Prager (medical oncologist at the Medical University of Vienna, Austria)
  • Prof. Christian Rolfo (medical oncologist at The Tisch Cancer Institute at Mount Sinai Health System, New York, USA)
  • Prof. Andrea Sartore-Bianchi (medical oncologist at Ospedale Niguarda and University of Milano, Italy)
  • Dr. Silvia Stacchiotti (medical oncologist at Oncologia Medica della Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy)

Medical writing support was provided by Mark English, PhD, Tricia Newell, PhD and Konstantina Grosios, PhD, of COR2ED GmbH. Subsequently the content was donated to the European Society for Medical Oncology (ESMO).

ESMO, COR2ED GmbH and the Scientific Directors wish to thank Bayer for their support with an Independent Medical Grant. Within the context of this Independent Medical Grant Bayer had no influence over the content.

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.

The creation of this content has largely been compiled from expert statements, literature review (of review articles, reports of small cohort studies and limited data from small prospective, randomised clinical trials) and expert guidance from the Scientific Directors as listed above.

ESMO thanks the following ESMO members who volunteered to review this section prior to its publication on OncologyPRO:

  • Ulrich Keilholz, Germany, ESMO Faculty member (Principles of Clinical Trials and Systemic Therapy, Melanoma, Tumour Immunology and Immunotherapy)
  • Maurice Pérol, France, member of the OncologyPRO Working Group
  • Benedikt Westphalen, Germany, member of the ESMO Translational Research and Precision Medicine Working Group

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.